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To the editor,  
Hidradenitis suppurativa (HS) is an inflammatory skin disease characterized by 
recurring painful, deep-seated inflammatory nodules, abscesses, sinus tracts, and 
scarring in the intertriginous areas.1 Bacteria may be involved in the pathogenesis of 
HS via follicular dysbiosis in the initial stages, and via biofilm in chronic sinus tracts.2 
Staphylococcus lugdunensis, a coagulase-negative staphylococcus (CNS), has been 
cultured from hidradenitis suppurativa nodules and abscesses. This points towards a 
role of S. lugdunensis in the aggravation and secondary colonization of HS 
lesions.3,4 S. lugdunensis has also been associated with biofilm-driven infections in 
different tissues.5 Therefore, we compared the in vitro growth, antibiotic susceptibility 
and biofilm-forming capabilities of S. lugdunensis strains from HS lesions with those 
of healthy controls and a reference strain.  
  This study has been approved by the ethical board and the data protection 
agency of Denmark. Informed consent was obtained from all participants. The S. 
lugdunensis strains were cultured from punch biopsies and swabs from active HS 
lesions. The controls comprised two strains from one healthy participant and the 
ATCC 49576 control strain. All strains were typed as described previously.6 
Rifampicin, tetracycline, clindamycin and doxycycline, commonly used to treat HS, 
were included in the experiments. Genetic relatedness of the S. lugdunensis strains 
was investigated with Pulsed-Field Gel Electrophoresis (PFGE)7 and analysed using 
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 S. lugdunensis was cultured in 12 out of 26 patients (46%). All strains showed 
growth in liquid medium in vitro, however after 6 hours the HS lesional strains and 
the control strain grew faster than the two strains from a healthy individual (HS 
versus healthy p<0.0354; control versus healthy p<0.0299). All strains were strong 
biofilm producers, but the healthy strains produced less biofilm when compared to 
HS lesional strains and the control strain. Clindamycin resistance was observed in 
41.6% of the strains (Table 1). Rifampicin was superior to clindamycin, doxycycline, 
and tetracycline in both growth-inhibition and biofilm eradication (p<0.05, Fig. 1). 
Five clusters of genetically closely related strains were identified, mostly in pairs. A 
high similarity was seen within the clusters especially for the two healthy strains. 
 
 The specific pathway by which bacteria are involved in the pathogenesis of 
HS needs further elucidation. Differences in the functional characteristics of S. 
lugdunensis strains from HS patients were identified in our study. The faster growth 
curves of the lesional HS and control strains than healthy strains, indicate a more 
pathogenic virulent status of the lesional S. lugdunensis strains.8 Nonetheless, the 
biofilm forming capacities were identical. The high clindamycin resistance rate of 
41.6% has previously been reported in more than 10% of the S. lugdunensis 
strains.9 Doxycycline appeared particularly effective at inhibiting the growth of S. 
lugdunensis, which may suggest that doxycycline could be used in the management 
of HS when CNS are present. 
 
All tested antibiotics significantly eradicated biofilm in the four tested strains. 
Interestingly, this also occurred in strain number 4, which showed resistance against 
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caused by a mutation whereby the receptor for the antibiotic is modified.10 Our 
findings in strain 4 imply that the efficacy of clindamycin in biofilm degradation is 
independent of its bactericidal activity. The close genetic relatedness of the strains, 
with five highly similar clusters, indicates that the number of specific strains that are 
involved in HS pathogenesis is limited. 
 
 A major strength of this study is the carefully optimized culture conditions for 
our experiments. A limitation is that by culturing the biopsies, and not using 
molecular bacterial sequencing such as  16S ribosomal RNA techniques, we 
possibly missed some bacterial strains. 
 
 In conclusion, we show that S. lugdunensis strains were more frequently 
resistant to antibiotics used to treat HS, and showed an increased biofilm production. 
Based on our current findings, it is conceivable that these characteristics may foster 
HS disease activity. A larger sample size across different HS phenotypes and 
anatomical regions with bacterial genome sequencing is needed for a better picture 
of the role of S. lugdunensis in HS.  
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Legend for figure 
Figure 1. Eradication of bacterial biomass in preformed biofilms exposed to 
rifampicin (0.0625 µg/mL), tetracycline (0.25 µg/mL), clindamycin (0.25 µg/mL) and 
doxycycline (0.125 µg/mL) for 24 hours. The graphs are showing HS strain number 4 
(a), HS strain number 5 (b), the healthy control strains (c) and the laboratory control 
strain (d).  The graphs are normalized to the growth controls (no stimuli added), 
which is depicted as 100% of biofilm formation.  Statistical significance is indicated 
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Table 
Table 1. Antimicrobial susceptibility and biofilm production pattern for all strains.  
 
 MIC (µg/mL)   
S. lugdunesis strains Rif Tet Clinda Doxy Antibiotic use  Biofilm  
production 
 
Strain 1 (biopsy) 0.03 0.25 >128 0.13 None Strong 
Strain 2 (biopsy)  0.06 0.25 0.50 0.13 None Strong 
Strain 3 (biopsy)  0.03 0.25 >128 0.13 None Strong 
Strain 4 (biopsy)  0.06 64 >128 4 Clindamycin lotion Strong 
Strain 5 (biopsy)      0.06 0.13 0.50 0.13 None Strong 
Strain 6 (biopsy)  0.03 0.25 0.25 0.13 Clindamycin lotion Strong 
Strain 7 (biopsy)  0.06 0.13 0.25 0.25 Unknown Strong 
Strain 8  (biopsy)  0.01 0.25 >128 0.13 None  Strong 
Strain 9 (biopsy)  0.03 0.50 >128 0.13 Clindamycin lotion Strong 
Strain 10 (swab) 0.06 0.50 0.50 0.25 None Strong 
Strain 11 (swab) 0.06 0.50 0.50 0.25 None Strong 
Strain 12 (swab) 0.06 0.25 0.25 0.25 None Strong 
Healthy control (biopsy) 0.06 0.25 0.25 0.13 None Strong 
Healthy control (swab) 0.06 0.25 0.25 0.13 None Strong 
Laboratory control strain  0.06 0.13 0.25 0.13 None Strong 
Rif, rifampicin; Tet, tetracycline; Clinda, clindamycin; Doxy, doxycycline 
Notes:  Resistance is indicated in bold with an underlining. (a) received topical clindamycin 
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